Peptide Schedule
DNSP-1111 residuesPPEAPAEDRSLEach bubble = one amino acid. Size = residue mass. Color = chemical class.DNSP-11 Dosage Calculator
DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is a synthetic 11-amino-acid peptide derived from the proprotein region of human glial cell line-derived neurotrophic factor (GDNF).
100mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 4.0 units on a U-100 syringe for a 100mcg dose. This vial will last 50 doses.
Cycle Planner
DNSP-11 Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~24+ hours (estimated from animal models, duration of effect up to 28 days)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
DNSP-11 Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
Note: GDNF propeptide-derived 11-amino-acid neuroprotective peptide. Intranasal or subcutaneous. Preclinical only — no human trials have been conducted. All dosing is extrapolated from rat and non-human primate studies.
About DNSP-11
DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is a synthetic 11-amino-acid peptide derived from the proprotein region of human glial cell line-derived neurotrophic factor (GDNF). It was identified through a post-translational processing model which predicted that the GDNF prosequence could be cleaved at internal dibasic endopeptidase sites to yield smaller, amidated bioactive peptides. In cell culture, DNSP-11 supports the survival of fetal mesencephalic dopaminergic neurons, increasing both cell number and neurite outgrowth. It blocks staurosporine- and gramicidin-induced cytotoxicity in dopaminergic B65 cells by preventing cytochrome c release from mitochondria. Importantly, its neuroprotective activity does not appear to depend on binding the canonical GFR-alpha-1 receptor used by full-length GDNF, suggesting a distinct signaling pathway involving ERK1/2 phosphorylation. In vivo, a single injection of DNSP-11 into the rat substantia nigra increased resting dopamine and DOPAC levels by approximately 100% with effects persisting up to 28 days. In 6-OHDA lesioned rats (a standard Parkinson's disease model), it reduced apomorphine-induced rotational behavior by roughly 50%. Intranasal administration studies in rats showed that 125-I-labeled DNSP-11 distributed throughout the brain within 30 minutes, reaching the striatum and substantia nigra. Repeated intranasal dosing at 300 mcg in rats increased dopamine turnover in both the striatum and substantia nigra. Non-human primate studies confirmed tolerability of repeated intranasal delivery at escalating doses up to 10 mg/day over 10 weeks without adverse behavioral effects or weight loss. All existing evidence comes from rodent and non-human primate studies. No human clinical trials have been initiated. The long-term safety profile in humans is completely unknown, and this compound should be considered strictly experimental.